Similarly, the phase 3 trials demonstrated that roxadustat was non-inferior to ESAs in Hb correction and maintenance in studies of incident (Provenzano et al., 2021b; Fishbane et al., 2022; Charytan et al., 2021) or prevalent (Fishbane et al., 2022; Charytan et al., 2021; Csiky et al., 2021; Chen et al., 2019b) DD-CKD patients. Here, GSTM1 is linked to chronic kidney disease.